#GIPR
$GIPR — Die jüngsten Analysen zu GIPR befassten sich mit erheblichen finanziellen Umstrukturierungsbemühungen und einer bemerkenswerten Divergenz technischer Indikatoren, neben Entwicklungen im Pharmasektor bezüglich GIPR-Agonisten.

https://market-scanner.net/de/tickers/GIPR.US

#ai #trading
GIPR.US — Zusammenfassung der KI-Analysen
Beschreibende, richtungsneutrale Zusammenfassung aktueller KI-Analysen.
market-scanner.net
November 17, 2026 at 5:46 PM
$GIPR — GIPR's recent analyses covered significant financial restructuring efforts and a notable divergence in technical indicators, alongside developments in the pharmaceutical sector related to GIPR agonists.

https://market-scanner.net/tickers/GIPR.US

#ai #trading
GIPR.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
November 17, 2026 at 5:46 PM
US MICRO CAP | PREMARKET | 2026-11-16 | 1/1

#POLA #YFOR #GIPR #AKAN #GP #AIMD #CLRO #OPTT #MicroCap #USStocks #StockMarket #Trading
November 16, 2026 at 1:00 PM
📈 Sub-$500M premarket prep — 2026-11-18

#$AZI: $12.75M convertible notes issued.
#$SMTK: merger partner seeks titanium buyers.
#$FRTT: 9M revenue +49% YoY; 92x rot.
#$GIPR: $9.1M property sales YTD.
#$POLA: No facility share sales since Oct 19.
November 18, 2026 at 8:53 AM
More intriguing Promethion-powered research from Dr. F Reimann & colleagues at Cambridge - distinct brain circuits mediate appetite responses to GIP receptor agonism vs antagonism! www.nature.com/articles/s42...
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism - Nature Metabolism
The study employs region-specific knockout of the glucose-dependent insulinotropic polypeptide receptor (GIPR) in either the area postrema or hypothalamus of mice to determine how GIPR agonism and ant...
www.nature.com
November 12, 2026 at 5:07 PM
Свалихте по-малко от другите на GLP-1 медикамент? Не е липса на воля.
Изследване, обсъдено в Nature (2026), свързва варианти в гените GLP1R и GIPR с това колко отслабваме и кой понася лечението по-трудно.
Тест още няма, но медицината става все по-лична.
November 11, 2026 at 5:23 AM
Retatrutide, Eli Lilly's investigational triple agonist, targets GLP-1R, GIPR & GCGR to regulate appetite, insulin secretion & energy metabolism. In Phase III, it achieved up to 20.9% mean weight loss at 80 weeks in adults with type 2 diabetes.

#TargetMol #Retatrutide #DrugDiscovery
November 13, 2026 at 9:38 AM
Randy J. Seeley, PhD (2026 Diabetes Research Day Keynote): the gut brain axis is the key metabolic regulator of body weight. Bile acid signaling and Reg3g gut barrier formation are necessary. Rebound weight gain is mechanism, not pharmacokinetics #Obesity #GLP1 #GIPR #Diabetes @seeleyrj.bsky.social
November 6, 2026 at 1:52 AM
GLP-1R and GIPR crosstalk got its own mechanistic paper in Cell Chem Biol this month. The dual-agonist conversation usually skips past why the two receptors even talk to each other. This is the why.
November 7, 2026 at 1:00 PM
Íslensk erfðagreining vísar ásökunum Kára á bug

Íslensk erfðagreining vísar þeim orðum Kára Stefánssonar fyrrverandi forstjóra á bug að félagið hafi farið með ósannindi í umfjöllun Bloomberg um rannsóknir tengdar þróun þyngdarstjórnunarlyfsins MariTide, sem nú er í klínískri þróun hjá Amgen.…
Íslensk erfðagreining vísar ásökunum Kára á bug
Íslensk erfðagreining vísar þeim orðum Kára Stefánssonar fyrrverandi forstjóra á bug að félagið hafi farið með ósannindi í umfjöllun Bloomberg um rannsóknir tengdar þróun þyngdarstjórnunarlyfsins MariTide, sem nú er í klínískri þróun hjá Amgen. Hvorki hafi verið sagt ósatt né staðreyndir rangfærðar um framlag fyrirtækisins og vísindamanna þess. Hvergi sé heldur fullyrt í greininni að vísindamenn Íslenskrar erfðagreiningar hafi fyrstir komið fram með kenningar um að GIPR-próteinið gæti tengst líkamsþyngd eins og sagt var í viðtalinu.
umlegacypressqsefc.com
November 9, 2026 at 5:50 PM
(US20260315614A1) antibody-conjugated GLP-1R/GIPR dual agonist peptides designed for prolonged exposure in obesity and diabetes. Key question: whether conjugation preserves balanced receptor activity while improving dosing intervals, tolerability and body-composition outcomes versus free agonists.
October 24, 2026 at 12:52 PM
GIPR +5.9% pre-market at $0.4369 on 2M shares. Catalyst: company announced full retirement of its Loci Capital financing relationship. Watching i… https://tapeboard.com/go/x/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=tapeboard&utm_content=gipr-up-1791362827&utm_term=scanner&s=GIPR
October 23, 2026 at 12:00 AM
Glycemic and bodyweight effects of GIPR coding variation reflect differences in surface expression and intrinsic functional impairment | Science Advances www.science.org/doi/10.1126/...
Glycemic and bodyweight effects of GIPR coding variation reflect differences in surface expression and intrinsic functional impairment
The glucose-dependent insulinotropic polypeptide receptor (GIPR) is a major therapeutic target in type 2 diabetes and obesity. Missense variation in GIPR could confer phenotypic effects through altera...
www.science.org
October 23, 2026 at 12:46 AM
www.youtube.com/watch?v=GIPr...

이거... 그거잖아... 초인싸... 초초초인싸... 크윽 눈부셔
최강이 만들어진 이유 [홀로라이브/햐쿠토 쿄코]
YouTube video by Ahoge 아호게
www.youtube.com
October 10, 2026 at 5:08 AM
After-hours movers tonight: gainers all nano-caps — #$SXTC +54%, #$BIYA +52%, #$MTEN +43%, all Chinese small-caps; #$GIPR +31% on a $708K cap. Losers: #$CRBU −38% (biotech), #$OLB −24% to $0.31 — the day's +111% pump fading. #$YEXT −10% on $649M. Never chase thin AH prints. [NOT FINANCIAL ADVICE, DYOR!]
October 6, 2026 at 10:24 PM
[ainet] [인실리코, 차세대 비만 치료제로 AI 설계 GIPR 차단제 ISM1354 지명] 인실리코의 창립자이자 공동 CEO인 알렉스 자보론코프 박사는 이 사안이 어디로 향하고 있는지에 대해 직설적으로 말한다.
www.ainet.link/29047
[인실리코, 차세대 비만 치료제로 AI 설계 GIPR 차단제 'ISM1354' 지명] 인실리코의 창립자이자 공동 CEO인 알렉스 자보론코프 박사는 이 사안이 어디로 향하고 있는지에 대해 직설적으로 말한다.
인실리코,차세대비만치료제로AI설계GIPR차단제'ISM1354'지명 초기동물·실험실데이터서경쟁화합물대비최소18배혈중노출…더넓은안전마진AI신약개발사
www.ainet.link
October 2, 2026 at 2:25 PM
$GIPR — Generation Income Properties (GIPR) financial restructuring and volatile market indicators dominated recent analyses.

Strong short-term buying pressure indicated by Money Flow Index (MFI).

https://market-scanner.net/tickers/GIPR.US

#ai #trading
GIPR.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
October 2, 2026 at 12:36 PM
NYSE Top 3 most-shorted Stocks (based on Shorted Share Volume not Dollar Value): $HYG 5,518,513 shares | $GIPR 2,583,223 shares | $LQD 2,525,441 shares | 2026-10-01
October 1, 2026 at 11:57 PM
Insilico Medicine Unveils Revolutionary GIPR Antagonist ISM1354 for Weight Management#GIPR_Antagonist#Insilico_Medicine#ISM1354
Insilico Medicine Unveils Revolutionary GIPR Antagonist ISM1354 for Weight Management
Insilico Medicine has announced the nomination of ISM1354, a new GIPR antagonist that shows promise in tackling obesity and related metabolic disorders using AI-driven drug discovery.
third-news.com
September 30, 2026 at 6:11 AM
Novo indgår milliardaftale med kinesisk kæmpe Læs mere👇 #dkbiz
Novo indgår milliardaftale med kinesisk kæmpe
Novo har indgået en licensaftale med den kinesiske medicinalkæmpe Jiangsu Hengrui Pharmaceuticalsom en GLP1R/GIPR-agonist i fase 1. Det fremgår af en meddelelse tirsdag morgen. Midlet har potentiale t...
finans.dk
September 29, 2026 at 5:57 AM
🫀 The next generation of GLP-1 drugs is targeting more pathways but also making heart effects less predictable. Surprising differences between mouse and human hearts are emerging.

Full story: www.news-medical.net/news/2026092... #GLP1 #Cardiology #Pharma
As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict
A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The autho...
www.news-medical.net
September 24, 2026 at 5:45 AM